cns & neurological disorders drug targets

Cells

Journal of cellular and molecular medicine

neurotoxicology

[1] Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour.

[2] The Role of Ca Signaling in Aging and Neurodegeneration: Insights from Models.

[3] transcranial sonography on parkinson′s disease and essential tremor

[4] treatment and rehabilitation in non-motor symptoms of parkinson’s disease

[5] can postural instability respond to galvanic vestibular stimulation in patients with parkinson’s disease?

[6] control of postural alignment in patients with parkinsons disease: analysis through postural software (sapo)

[7] the parkinson care advocate: integrating care delivery

[8] neuroimmunology of the interleukins 13 and 4

[9] the effects of melatonin with memantin on mptp-induced parkinson model in male mice

[10] Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.

[11] Neuroprotective Properties of Standardized Extracts of Hypericum perforatum on Rotenone Model of Parkinson's Disease.

[12] Delusions and visual hallucinations in a patient with Parkinson's disease with dementia showing pronounced Lewy body pathology in the nucleus basalis of Meynert.

[13] Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.

[14] PARKİNSON HASTALIĞININ SES SİNYALLERİ ÜZERİNDEN MAKİNE ÖĞRENMESİ TEKNİKLERİ İLE TANIMLANMASI

[15] GRP78/BIP/HSPA5 as a Therapeutic Target in Models of Parkinson’s Disease: A Mini Review

[16] The Swallowing Clinical Assessment Score in Parkinson’s Disease (SCAS-PD) Is a Valid and Low-Cost Tool for Evaluation of Dysphagia: A Gold-Standard Comparison Study

[17] PARKİNSON HASTALIĞININ SES SİNYALLERİ ÜZERİNDEN MAKİNE ÖĞRENMESİ TEKNİKLERİ İLE TANIMLANMASI

[18] Changes of Retina Are Not Involved in the Genesis of Visual Hallucinations in Parkinson’s Disease

[19] Generation of CSi001-A, a transgene-free, induced pluripotent stem cell line derived from a Parkinson Disease (PD) patient.

[20] Generation of gene-corrected iPSC line from Parkinson's disease patient iPSC line with alpha-SNCA A53T mutation.

[21] Mental Singing Reduces Gait Variability More Than Music Listening for Healthy Older Adults and People With Parkinson Disease.

[22] Antimicrobial activities of Parkinsoniaaculeata and Prosopiskoelziana extracts against pathogenic fungi and bacteria (Staphylococcus aureus, S. epidermidis,S. pyogenes,Pseudomonas Aeruginosa, Escherichia Coli, Aspergillus niger, A. flavus, A. fumigatus,F. solani,Microsporum gypseum, M. mcanis, Trichophyton verrucosum,T. rubrum and Candida albicans)

[23] Deep brain stimulation for Parkinson's disease modulates high-frequency evoked and spontaneous neural activity.

[24] Assessment of cardiorespiratory fitness using submaximal protocol in older adults with mood disorder and Parkinson's disease

[25] Outcomes from deep brain stimulation targeting subthalamic nucleus and caudal zona incerta for Parkinson's disease.

[26] Acute Post-stroke Hemiparkinsonism and Hemiparesis: A Unique Case with Successful Therapy.

[27] AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.

[28] Early Experience With New Generation Deep Brain Stimulation Leads in Parkinson's Disease and Essential Tremor Patients.

[29] A Stage-Based Approach to Therapy in Parkinson's Disease.

[30] Biomechanical System Versus Observational Rating Scale for Parkinson’s Disease Tremor Assessment

[31] The embodiment of language in tremor-dominant Parkinson's disease patients

[32] Burden of non-motor symptoms in unclear parkinsonism and tremor: A study with [¹²³I]FP-CIT SPECT

[33] Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease

[34] Quality of life in Parkinson’s disease patients: progression markers of mild to moderate stages

[35] Clinical profile of parkinson's disease: Experience of niger

[36] Translational methods to detect asymmetries in temporal and spatial walking metrics in parkinsonian mouse models and human subjects with Parkinson’s disease

[37] Validity of MobilityLab (version 2) for gait assessment in young adults, older adults and Parkinson's disease.

[38] Measuring Hand Dexterity in People With Parkinson's Disease: Reliability of Pegboard Tests.

[39] Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease

[40] The CuePed Trial: How Does Environmental Complexity Impact Cue Effectiveness? A Comparison of Tonic and Phasic Visual Cueing in Simple and Complex Environments in a Parkinson's Disease Population with Freezing of Gait.

[41] The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function.

[42] Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression.

[43] Associations between cerebrovascular risk factors and parkinson disease.

[44] Glucocerebrosidase and its relevance to Parkinson disease.

[45] Drug induced parkinsonism: Symptomatic beyond 22 months.

[46] "You have to know why you're doing this": a mixed methods study of the benefits and burdens of self-tracking in Parkinson's disease.

[47] Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.

[48] The daily lives of people with Parkinson's disease

[49] Dopaminergic modulation of the praxis network in Parkinson's disease.

[50] Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases.

[51] Effectiveness of SaeboReJoyce in the Evaluation of the Improvement of the Occupational Performance in Parkinson’s Disease: An Outcome Research

[52] Lipid Analysis of the 6-Hydroxydopamine-Treated SH-SY5Y Cell Model for Parkinson's Disease.

[53] Brain-First versus Gut-First Parkinson's Disease: A Hypothesis.

[54] A Fully Automatic Framework for Parkinson's Disease Diagnosis by Multi-Modality Images.

[55] Psychological Benefits of Nonpharmacological Methods Aimed for Improving Balance in Parkinson’s Disease: A Systematic Review

[56] Emergencies in an advanced stage Parkinson's disease patient.

[57] Difficulties with Invasive Risk Stratification Performed Under Anesthesia in Pediatric Wolff-Parkinson-White Syndrome.

[58] Nucleus basalis of Meynert neuronal activity in Parkinson's disease.

[59] Study protocol for a single-blind randomised controlled trial to evaluate the clinical effects of an Integrated Qigong exercise intervention on freezing of gait in Parkinson's disease.

[60] Metabolic response to Parkinson's disease recapitulated by the haploinsufficient diploid yeast cells hemizygous for the adrenodoxin reductase gene.

[61] Effect of stromal cell-derived factor-1/CXCR4 axis in neural stem cell transplantation for Parkinson's disease.

[62] Tai Chi and Parkinson's disease (PD): A systematic overview of the scientific quality of the past systematic reviews.

[63] Changes in Phonation and Their Relations with Progress of Parkinson’s Disease

[64] Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: Results from a pilot randomized controlled trial.

[65] 'Draw your pelvis' test for assessing pelvic schema in people with Parkinson's disease: a validity and reliability study.

[66] Correction: Trans-blood brain barrier delivery of dopamine-loaded nanoparticles reverses functional deficits in parkinsonian rats (ACS Nano (2015) 9:5 (4850-4871) DOI: 10.1021/nn506408v)

[67] Impact of motor fluctuations on real-life gait in Parkinson's patients.

[68] Centenary of Tretiakoff’s thesis on the morphology of Parkinson’s disease, evolved on the grounds of encephalitis lethargica pathology

[69] Altered Global Synchronizations in Patients With Parkinson's Disease: A Resting-State fMRI Study.

[70] Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation

[71] Parkinsonism in poets and writers.

[72] Impact of dopamine and cognitive impairment on neural reactivity to facial emotion in Parkinson's disease.

[73] Communication impairment in Parkinson's disease: Impact of motor and cognitive symptoms on speech and language.

[74] The Parkinson's Disease Mendelian Randomization Research Portal.

[75] COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of home-based, online cognitive training on cognition and brain networks in Parkinson's disease.

[76] Circulating amino acid signature in older people with Parkinson's disease: A metabolic complement to the EXosomes in PArkiNson Disease (EXPAND) study

[77] Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson’s disease using ¹⁸F-FDG PET imaging

[78] Classification of Patients with Parkinson’s Disease Using Medical Imaging and Artificial Intelligence Algorithms

[79] A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson’s Disease in Japan

[80] Clinical-Pharmacogenetic Predictive Models for Time to Occurrence of Levodopa Related Motor Complications in Parkinson’s Disease

[81] Acupuncture Inhibits the Increase in Alpha-Synuclein in Substantia Nigra in an MPTP- Induced Parkinsonism Mouse Model.

[82] tDCS-Enhanced Consolidation of Writing Skills and Its Associations With Cortical Excitability in Parkinson Disease: A Pilot Study

[83] Somatosensory Training Improves Proprioception and Untrained Motor Function in Parkinson's Disease.

[84] New awakenings: current understanding of sleep dysfunction and its treatment in Parkinson's disease.

[85] Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.

[86] Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

[87] Impairment in Theory of Mind in Parkinson's Disease Is Explained by Deficits in Inhibition.

[88] Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities.

[89] Impact of orthostatic hypotension on wheelchair use in patients with Parkinson's disease.

[90] Analyzing Apomorphine-Mediated Effects in a Cell Model for Parkinson's Disease with Partial Least Squares Structure Equation Modeling.

[91] Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease.

[92] [Subjective and objective subtypes of excessive daytime sleepiness in Parkinson's disease].

[93] Orthostatic Hypotension in Parkinson Disease

[94] Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer

[95] Orthostatic hypotension in Parkinson disease: A 7-year prospective population-based study

[96] Detection of orthostatic hypotension with ambulatory blood pressure monitoring in parkinson’s disease

[97] Nonmotor symptoms in Parkinson's disease: classification and management

[98] Therapeutic effects of forced exercise cycling in individuals with Parkinson's disease.

[99] Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease

[100] Boxing for Parkinson's Disease: Has Implementation Accelerated Beyond Current Evidence?

[101] Glial cells in intracerebral transplantation for Parkinson's disease.